

**INTERIM ANALYSIS OF PHASE Ib/II STUDY OF
ERIBULIN AND PEMBROLIZUMAB COMBINATION REGIMEN IN
METASTATIC TRIPLE NEGATIVE BREAST CANCER PRESENTED AT
SAN ANTONIO BREAST CANCER SYMPOSIUM**

that the results of an interim analysis of a Phase Ib/II clinical study (Study 218) of its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: Halaven[®], eribulin) in combination with the anti-PD-1 antibody pembrolizumab developed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the U.S. and Canada), in patients with metastatic triple-negative breast cancer have been presented at the 39th Annual San Antonio Breast Cancer Symposium held from December 6 to 10, 2016.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3

3. About triple-negative breast cancer

Triple-negative breast cancer is a type of breast cancer where the cancer cells tested negative for expression of estrogen receptors, progesterone receptors and HER-2 receptors. Since the tumor cells lack the necessary receptors, common treatments like hormone therapy and drugs that target HER-2 are ineffective. This remains a disease with significant unmet medical need. Therefore, the